Please assess the completion status of the following clinical trial:

Trial Title: HIV-1 Vaccine Test in Uninfected Adult Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~A participant must meet all of the following criteria:~* 18 to 40 years old.~* Available for follow-up for the duration of the study (12 months).~* Able to provide proof of identity to the acceptance of the study clinician completing the enrollment process.~* Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly.~* Able and willing to sign the informed consent form.~* Willing to receive HIV test results and willing to abide by NIH guidelines for partner notification of positive HIV results.~* Willing to have blood samples used for future research.~* Willing to discuss HIV infection risks and amenable to risk reduction counseling.~* In good general health without clinically significant medical history.~* Physical examination and laboratory results without clinically significant findings within the 28 days prior to enrollment.~Laboratory Criteria within 28 days prior to enrollment:~* Hematocrit greater than or equal to 34 percent for women; greater than or equal to 38 percent for men.~* WBC count: Non-African Americans equals 3,300-12,000 cells/mm(3); African-Americans equals 2,500-12,000 cells/mm(3) (in the absence of clinical or pathological etiology).~* Differential either within institutional normal range or accompanied by site physician approval.~* Total lymphocyte count: Non-African Americans greater than or equal to 800 cells/mm(3); African Americans greater than or equal to 650 cells/mm(3) (in the absence of clinical or pathological etiology).~* Platelets equals 125,000-550,000/mm(3).~* ALT (SGPT) less than or equal to 1.5 times upper limit of normal.~* Serum creatinine less than or equal to 1.3 mg/dL.~* Normal urinalysis defined as negative glucose, negative or trace protein, and negative or trace hemoglobin (blood).~* Negative FDA-approved HIV blood test.~* Negative Hepatitis B surface antigen.~* Negative anti-HCV or negative HCV PCR if the anti-HCV is positive.~Female-Specific Criteria:~* Negative beta-HCG pregnancy test for women presumed to be of reproductive potential.~* A female participant must meet one of the following criteria:~No reproductive potential because of menopause \[one year without menses\] or because of a hysterectomy, bilateral oophorectomy, or tubal ligation,~Or~-Participant agrees to be heterosexually inactive at least 21 days prior to enrollment and throughout the duration of the study,~Or~* Participant agrees to consistently practice contraception at least 21 days prior to enrollment and throughout the duration of the study by one of the following methods:~* condoms, male or female, with or without a spermicide.~* diaphragm or cervical cap with spermicide.~* intrauterine device.~* contraceptive pills, Norplant, or Depo-Provera.~* male partner has previously undergone a vasectomy for which there is documentation.~EXCLUSION CRITERIA:~A volunteer will be excluded if one or more of the following conditions apply:~-Woman who is breast-feeding.~Volunteer has received any of the following substances:~* HIV vaccines in a prior clinical trial.~* Immunosuppressive or cytotoxic medications within the past six months with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis.~* Blood products within 120 days prior to HIV screening.~* Immunoglobulin within 60 days prior to HIV screening.~* Live attenuated vaccines within 30 days prior to initial study vaccine administration.~* Investigational research agents within 30 days prior to initial study vaccine administration.~* Medically indicated subunit or killed vaccines ( e.g., influenza, pneumococcal, or allergy treatment with antigen injections) within 14 days of study vaccine administration.~* Current anti-TB prophylaxis or therapy.~Volunteer has a history of any of the following clinically significant conditions:~* Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty angioedema, or abdominal pain.~* Autoimmune disease or immunodeficiency.~* Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids.~* Diabetes mellitus (type I or II), with the exception of gestational diabetes.~* Thyroid disease including history of thyroidectomy and diagnoses that required medication within the past 12 months.~* Serious angioedema episodes within the previous 3 years or requiring medication in the previous 2 years.~* Hypertension that is not well controlled by medication or is more than 150/100 at enrollment.~* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~* Syphilis infection that is active or a positive serology due to a syphilis infection treated less than six months ago.~* Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study.~* Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring prolonged treatment more than 3 years ago.~* Asplenia or any condition resulting in the absence or removal of the spleen.~* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment.~* Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgement of the investigator, would interfere with or serve as a contraindication to protocol adherence or a volunteer's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete